Eukles Asset Management Has $5.11 Million Position in ResMed Inc. (NYSE:RMD)

Eukles Asset Management reduced its position in shares of ResMed Inc. (NYSE:RMD) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,333 shares of the medical equipment provider’s stock after selling 933 shares during the period. ResMed accounts for approximately 2.2% of Eukles Asset Management’s portfolio, making the stock its 10th largest position. Eukles Asset Management’s holdings in ResMed were worth $5,107,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Savant Capital LLC lifted its holdings in ResMed by 4.7% in the 4th quarter. Savant Capital LLC now owns 10,796 shares of the medical equipment provider’s stock worth $2,469,000 after buying an additional 487 shares during the period. Kestra Private Wealth Services LLC lifted its stake in ResMed by 116.4% in the fourth quarter. Kestra Private Wealth Services LLC now owns 8,743 shares of the medical equipment provider’s stock worth $1,999,000 after acquiring an additional 4,702 shares during the period. Empowered Funds LLC boosted its holdings in ResMed by 47.5% in the fourth quarter. Empowered Funds LLC now owns 12,110 shares of the medical equipment provider’s stock valued at $2,769,000 after acquiring an additional 3,902 shares in the last quarter. Hendershot Investments Inc. increased its position in ResMed by 2.1% during the 4th quarter. Hendershot Investments Inc. now owns 45,456 shares of the medical equipment provider’s stock valued at $10,395,000 after purchasing an additional 914 shares during the period. Finally, Wilmington Savings Fund Society FSB raised its holdings in ResMed by 12.5% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 888 shares of the medical equipment provider’s stock worth $203,000 after purchasing an additional 99 shares in the last quarter. 54.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on RMD. Robert W. Baird lifted their target price on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. KeyCorp lifted their price objective on ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. UBS Group raised ResMed from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 31st. The Goldman Sachs Group started coverage on ResMed in a research report on Thursday, January 16th. They set a “buy” rating on the stock. Finally, Stifel Nicolaus began coverage on ResMed in a report on Friday, December 13th. They issued a “hold” rating and a $250.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, ResMed has an average rating of “Moderate Buy” and an average price target of $244.73.

ResMed Stock Performance

Shares of RMD stock opened at $236.84 on Monday. The company has a market capitalization of $34.78 billion, a price-to-earnings ratio of 27.96, a price-to-earnings-growth ratio of 1.57 and a beta of 0.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. ResMed Inc. has a one year low of $170.56 and a one year high of $263.05. The company’s 50-day moving average is $239.18 and its 200 day moving average is $237.59.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Sell-side analysts expect that ResMed Inc. will post 9.44 EPS for the current fiscal year.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed’s payout ratio is 25.03%.

Insider Transactions at ResMed

In related news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the completion of the sale, the director now directly owns 77,218 shares in the company, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Witte Jan De sold 796 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the transaction, the director now owns 6,723 shares in the company, valued at $1,672,749.63. This represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,094 shares of company stock worth $2,704,941 over the last quarter. 0.71% of the stock is currently owned by insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.